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Summary c-erbB-2 protein expression was investigated immunohistochemically in frozen thyroid tissue
specimens from 42 patients using a polyclonal sheep antibody. c-erbB-2 immunoreactivity was detected in 12
out of 17 papillary carcinomas, while no c-erbB-2 protein immunostaining was seen in cases of follicular
adenoma (five cases), follicular carcinoma (five cases) or medullary carcinoma (one case), nor in cases of
non-neoplastic tissue, including normal thyroid tissue from tumour-bearing glands. RNA was extracted from
51 thyroid tissue samples from 34 of the above patients, and c-erbB-2 mRNA was analysed by slot-blot
hybridisation. c-erbB-2 mRNA was detectable in all samples, but papillary carcinomas and lymph node
metastases showed significantly higher levels of c-erbB-2 mRNA compared to non-neoplastic tissue.
The present demonstration of positive c-erbB-2 immunostaining in papillary thyroid carcinomas is contra-
dictory to previous findings on formalin-fixed, paraffin-embedded material, and emphasises the importance of
tissue quality for c-erbB-2 protein detection.
During recent years much has been done to elucidate the role
of growth factors and oncogenes in the growth and function
of normal thyroid follicular cells and in the development and
maintenance of thyroid tumours.
The c-erbB-2 oncogene encodes a 185 kilodalton trans-
membrane glycoprotein with tyrosine kinase activity (Cous-
sens et al., 1985; Akiyama et al., 1986). This protein is closely
related to, but yet distinct from the EGF-receptor, encoded
for by the c-erbB proto-oncogene (Schechter et al., 1985).
Recently, a ligand has been proposed for the putative c-erbB-
2 growth factor receptor (Lupu et al., 1990). The c-erbB-2
oncogene has been found to be amplified and/or over-
expressed at mRNA or protein level in a number of human
adenocarcinomas, those of the breast being most extensively
studied (Slamon et al., 1987; 1989; van de Vijver et al., 1987;
1988; Venter et al., 1987).
c-erbB-2 protein overexpression is currently being
evaluated as a potential risk factor in breast cancer patients
(Gullick et al., 1991; Lovekin et al., 1991; O'Reilly et al.,
1991; Winstanley et al., 1991).
An analysis of c-erbB-2 and c-erbB mRNA expression in
thyroid tumours by RNA slot blot hybridisation demon-
strated two- to three-fold higher levels of c-erbB-2 and c-erbB
RNA in three out of five papillary carcinomas and three
papillary lymph node metastases, as compared to non-
tumour tissue (Aasland et al., 1988). The higher levels of
expression of c-erbB and c-erbB-2 mRNA in the papillary
carcinomas were much lower than the levels associated with
gene amplification. Southern blot analysis showed no
amplification or rearrangements of the c-erbB-2 gene (Aas-
land et al., 1988). The results were pursued in a comprehen-
sive analysis of the c-erbB and c-erbB-2 proto-oncogenes in
human thyroid neoplasia, using Southern blot hybridisation
to detect gene amplification or rearrangement, and
immunocytochemistry to detect overexpression of c-erbB-2
oncoprotein (Lemoine et al., 1990a). The Southern blot study
showed no abnormality of either structure or gene copy
number of the c-erbB or c-erbB-2 proto-oncogenes in 38
thyroid tumour samples, including 17 papillary carcinomas.
Immunohistochemical staining of paraffin sections of 106
tumour specimens (24 papillary carcinomas) from
pathological archives showed no cases of overexpression of
c-erbB-2 proto-oncogene (Lemoine et al., 1990a).
We have now extended these investigations by studying
c-erbB-2 protein expression immunohistochemically in a
series of thyroid tissue samples using fresh, frozen tissue,
considering that a modest expression might be lost due to
tissue processing when immunostaining is performed on
formalin-fixed, paraffin-embedded material. In a number of
the same tumours, c-erbB-2 mRNA expression has been
analysed by slot blot hybridisation.
Materials and methods
Tissue samples
Fresh thyroid tissue was obtained from 42 patients subjected
to either partial or total thyroidectomy between January 1990
and May 1991 at Haukeland University Hospital, Bergen,
Norway. Immediately after excision, samples were cut from
the surgical specimen(s), and each sample divided in two
parts. One part was frozen directly in liquid nitrogen and
stored at - 80°C for use in nucleic acid analysis.
The other part, intended for frozen sections, was immersed
in Histocon transport medium (Histolab, Gothenburg,
Sweden), and the following freezing procedure was completed
within one hour. The pieces of tissue were embedded in
Tissue Tek (Miles Scientific, Naperville, II.) and frozen on
cryostat bolts in isopentane precooled to liquid nitrogen
temperature. The samples were stored at - 80°C.
The biopsies were classified according to conventional
histopathological criteria, as defined by WHO (Hedinger,
1988), and the lesions included in this study, are listed in
Table I. Two or more samples were obtained from each
patient, the series comprising 115 samples from 42 patients in
all. The histology of all specimens was examined by one of
the authors (LAA).
Immunohistochemistry
Sections were cut 6 gim thick in a frozen microtome, fixed in
cold acetone for 10 min, and air dried. After a short rinse in
PBS (0.01 M phosphate buffered 0.15 M saline, pH 7.3), sec-
tions were treated with 1% hydrogen peroxide (H202) in
methanol for 30 min to block endogenous peroxidase
activity, then rinsed in PBS again. After incubation for
30 min at room temperature with normal rabbit serum
(Dakopatts, Copenhagen, Denmark) diluted 1:10 in PBS,
sections were incubated overnight (18-22 h) at 4°C with a
polyclonal sheep antibody to human c-erbB-2 oncoprotein
(OA-11-854, batch no. 02846, Cambridge Research Bio-
chemicals, Cambridge, UK). The antibody was used at dilu-
tion 1:500. After rinsing in PBS, sequential incubations with
secondary antibody (biotinylated rabbit anti sheep IgG from
Vector Laboratories, Burlingame, CA) at dilution 1: 100 and
AB-complex (10jg ml-' avidin and 2.5 Lg ml1' biotin-
labelled peroxidase from Vectastain ABC kit, Vector
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Table I Main histopathological diagnosis for patients included in
c-erbB-2 protein immunohistochemical study
Histopathological
diagnosis No. ofpatients
Diffuse hyperplasia 5
(Thyreotoxicosis)
Colloid goitre 11
Follicular adenoma 3
Follicular carcinoma 5
Papillary carcinoma 17a
Medullary carcinoma I
aThree patients presented only metastatic tissue.
Laboratories) followed, 30 min each, at room temperature.
The sections were immersed in DAB colouring solution
(0.03% 3'3 diaminobenzidine tetrahydrochloride [Sigma, St.
Louis, Missouri] and 0.02% H202 in PBS) for 5 min,
counterstained with haematoxylin, dehydrated and mounted.
All dilutions of antibodies, normal serum and AB-complex
were made with PBS containing 5% BSA (bovine serum
albumin) as the diluent.
A negative control was included for each specimen,
exchanging the primary antibody with PBS in duplicate sec-
tions (Figure 1f). Positive control specimens were used
routinely to check the procedure. The immortalised human
thyroid epithelial cell line SGHTL-34 (Whitley et al.,1987;
Aasland et al., 1990) was used as positive control. In our
laboratory, this cell line has been shown to express c-erbB-2
(G.O. Ness and JRL, personal communication). Incubation
of the primary antibody with the corresponding c-erbB-2
peptide (OP-11-3540, Cambridge Research Biochemicals)
before applying on sections was done to ensure antibody
specificity (Figure le). All controls gave satisfactory results.
To confirm the results, a second, monoclonal antibody to
c-erbB-2 protein (OP15, lot no. 7900305, Oncogene Science,
Manhasset, NY) was used. The staining procedure was per-
formed as described above, except that the sections were
incubated with the primary antibody at dilution 1:40 for 1 h,
and the secondary antibody was biotinylated rabbit anti
mouse IgG (Dakopatts) diluted 1:200.
Figure 1 Immunohistochemical localisation of c-erbB-2 protein in frozen sections of papillary thyroid carcinomas, by the
avidin-biotin-peroxidase method employing a polyclonal sheep antibody, as described in Materials and methods. a, Primary tumour
with membrane reactivity; b, primary tumour with cytoplasmic reactivity; c, primary tumour without reactivity; d, lymph node
metastasis with membrane and cytoplasmic reactivity; e and f, sections from the same tumour as in d, showing e, absence of
staining following preincubation of antibody with peptide immunogen, and f, control in which primary antibody was omitted.
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RNA extraction
RNA was extracted from 51 biopsies taken from 34 of the
above patients, providing the following cases: six samples of
histologically normal thyroid tissue (one sample taken from a
patient with a follicular adenoma, the others taken from
patients with papillary carcinomas), five diffuse hyperplasias,
12 colloid goitres, five follicular adenomas, four follicular
carcinomas (three primary tumours and one metastasis), 11
papillary carcinomas (primary tumours) and eight lymph
node metastases from papillary carcinomas.
Tissue samples were evacuated from liquid nitrogen, in-
stantly minced and lysed in 4 M guanidinium isothiocyanate,
as described by Aasland et al. (1988). Ultracentrifugation
through a cesium chloride cushion was carried out at
27,000 r.p.m. for 18 h. Pelleted RNA was further processed
as described (Aasland et al., 1988).
Slot blot analysis
RNA was denatured at 56°C for 15 min in 20% formal-
dehyde and 30% 20 x SSC (standard saline-citrate) and ap-
plied to nylon membranes (NY 13N by Schleicher & Schuell,
Dassel, Germany) in a vacuum slot blot apparatus
(Schleicher & Schuell). For each case, a set of 2, 6 and 12jig
total RNA was applied, if there was a sufficient amount of
RNA available. RNA concentrations were determined
spectrophotometrically. As as internal control, some samples
were included on all slot blot membranes. Prehybridisation
and hybridisation were carried out in 50% formamide at
42°C in a hybridisation oven (Hybaid Ltd., Teddington, UK)
as described (Sambrook et al., 1989). DNA fragments were
prepared from plasmids and 32P-labelled ([X-32P]dCTP from
Amersham, Aylesbury, UK) to high specific activity using the
oligo-labelling technique (Feinberg & Vogelstein, 1983). The
probe was a purified fragment of the cloned human c-erbB-2
gene, a partial c-erbB-2 cDNA 1.6 kbp EcoRI fragment of
pCER 204 (Yamamoto et al., 1986). Blots were washed to
high stringency (65°C, 0.2 x SSC with 0.1% NaPPi and 0.1%
SDS [sodium dodecyl sulphate]) and exposed on X-ray films
(XAR 5 by Kodak, Rochester, NY) in the presence of inten-
sifying screens at - 800C.
After stripping of slot blot membranes in 0.1% SDS at
90°C for 7 min, hybridisation with a 28S rRNA probe was
performed according to the same procedure. The 28S rRNA
probe was the 1.4 kbp BamHI fragment of pA (Dr I.L.
Gonzales, personal communication). Analysis of autoradio-
grams was performed by densitometric scanning using an
Enhanced Laser Densitometer (LKB Products, Bromma,
Sweden). The relative levels of c-erbB-2 mRNA expression
were estimated from scanning results as the amount of
radioactive probe hybridised to each RNA sample relative to
the amount of 28S rRNA in each sample.
Results
Immunohistochemnistry
Employing the polyclonal sheep antibody OA-11-854, no
c-erbB-2 protein immunostaining was seen in cases of colloid
goitre, diffuse hyperplasia, follicular adenoma or follicular
carcinoma, in the only medullary carcinoma included in the
series nor in normal thyroid follicular epithelium, including
microscopically normal tissue from tumour-bearing thyroid
glands.
In the papillary carcinoma group, c-erbB-2 immunostain-
ing was present in tumour samples from 12 of the 17 patients
(Figure 1). Details on these patients are given in Table II.
The positively stained samples included 11 out of 14
primary tumours. From three patients, tissue from the
primary tumour was not available, but samples from lymph
node metastases were obtained. In two of these cases, no
immunoreactivity was found, while the third patient had
immunopositive epithelium in all three nodes available.
Table II c-erbB-2 immunostaining in tissue samples from 17 patients
with papillary thyroid carcinomas
No. ofcases withpositive
c-erbB-2 immunostainingl
Tissue category no. ofcases analysed
Primary tumour 11/14
Non-tumour tissuea 0/12
Follicular adenoma 0/2
Lymph node metastasis 5/8
aIncluding normal and goitrous tissue.
Lymph node metastases were provided from five of the 14
primary tumours. Lymph nodes with positive c-erbB-2
immunostaining also had immunopositive primary tumours
(four cases). In contrast, neither the primary tumour nor the
metastasis showed c-erbB-2 immunoreactivity in one case.
Immunoreactivity was confined to tumour cells. The stain-
ing was specific and reproducible, although staining intensity
was uniformly rather weak. In most cases, specific membrane
staining as well as a weak cytoplasmic positivity of tumour
cells were seen. Two cases showed a predominantly cytoplas-
mic reaction, while two cases demonstrated almost exclus-
ively membrane staining. Two or more positive samples from
the same patient (from different parts of the tumour or from
metastases) showed the same staining pattern. The staining
was homogeneously distributed in the sections. Apart from
tumour cells, staining was seen in the colloid of thyroid
follicles, independent of tissue diagnosis. Colloid staining was
in most cases relatively strong.
Corresponding results were obtained using the monoclonal
antibody OP15, with the exception that a weak cytoplasmic
reaction was seen in one papillary carcinoma (patient no.
125) which did not show immunoreactivity when examined
with the polyclonal antibody OA-11-854. With the mono-
clonal antibody, only cytoplasmic staining was present, while
membrane staining as well as cytoplasmic reactivity were
detectable with the polyclonal antibody.
RNA analysis
Relative amounts of c-erbB-2 mRNA from RNA slot blot
hybridisation analysis are presented in Figure 2. An example
of autoradiograms of slot blot membranes is given in Figure
3. The hybridisation experiments showed that papillary car-
cinomas and lymph node metastases expressed higher levels
of c-erbB-2 mRNA relative to non-neoplastic tissue (normal
thyroid tissue, diffuse hyperplasia and colloid goitre) (t-test:
P<0.00l).
In two samples showing increased c-erbB-2 mRNA expres-
sion, the corresponding protein was not detected with the
immunohistochemical assay (patients no. 91 and 114). The
other cases showing increased c-erbB-2 mRNA expression
also showed c-erbB-2 protein product expression immunohisto-
chemically.
Three patients (no. 102, 117 and 122) showed c-erbB-2
protein immunoreactivity even though their c-erbB-2 mRNA
levels were not different from those of the reference group
(Figure 2).
In the papillary carcinoma group, two lymph node metast-
ases (patients no. 136 and 139) demonstrated the lowest
levels of c-erbB-2 mRNA. These were the only two papillary
metastatic deposits included in the mRNA analysis in which
no c-erbB-2 protein was detected.
Discussion
In this study we provide evidence that c-erbB-2 protein ex-
pression is a feature of papillary thyroid carcinomas, in
contrast to non-neoplastic thyroid tissue. We have inves-
tigated c-erbB-2 protein expression immunohistochemically in
a series of thyroid tissue samples, using fresh, frozen tissue
obtained directly during surgery, and a polyclonal antibodyc-erbB-2 IN PAPILLARY THYROID CARCINOMAS 835
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Figure 2 Relative levels of c-erbB-2 mRNA in thyroid tissue samples as measured by densitometric scanning of autoradiograms
(see Materials and methods). The unit of expression is arbitrary. Tissue samples are denoted by the patient number followed by a
sample number; the sample number is omitted when the value represents a mean of two equivalent samples. The biopsies are
arranged by increasing level of expression, and are grouped according to histological classification as follows: FA: follicular
adenoma; FC: follicular carcinoma; PC: papillary carcinoma; NT: normal thyroid tissue; CG: colloid goitre and DH: diffuse
hyperplasia. * indicates lymph node metastasis, # indicates positive c-erbB-2 immunostaining.
Figure 3 Example of autoradiograms from RNA slot blot hy-
bridisation showing RNA expression of c-erbB-2 and 28S rRNA
in tissue samples from papillary thyroid carcinomas (PC) and
lymph node metastases from papillary carcinomas (LM). Samples
of 61tg RNA were slot blotted onto nylon membranes and
hybridised to the probes indicated as described in Materials and
methods.
to pl85crbB-2. Lemoine and coworkers were not able to detect
any c-erbB-2 overexpression in 24 papillary carcinomas using
formalin-fixed, paraffin-embedded material from pathological
archives (Lemoine et al., 1990a). Natali et al. (1990), how-
ever, demonstrated c-erbB-2 expression in two out of nine
thyroid carcinomas (no further classification given) using
frozen tissue. For breast cancer tissue, where c-erbB-2 expres-
sion has been most widely studied, the discrepancy between
results from formalin-fixed and frozen material has been
emphasised by Slamon et al. (1989), who reported that in
virtually every case there was some reduction in immunohis-
tochemical staining with polyclonal antiserum when compar-
ing fixed to frozen tissue. In tumours expressing very high
levels, the protein was visible by immunostaining in tissue
prepared by either method. The problem was more
significant in samples expressing moderate levels of protein
since many of them completely lost their immunohis-
tochemical reactivity during formalin fixation and paraffin
embedding. Slamon concludes that the problem of loss of
antigenic immunoreactivity during fixation can be overcome
by using frozen tissue samples (Slamon et al., 1989).
The difference between fixed and frozen material for c-
erbB-2 oncoprotein detection has also been demonstrated for
bladder cancer (Wright et al., 1990). Recently, a novel
monoclonal antibody to c-erbB-2 protein, NCL-CBl1, has
been introduced, and reported to be highly effective for
immunohistochemistry using paraffin-embedded material.
Even with this antibody, however, the authors cannot ex-
clude that some immunopositive cases might be lost due to
fixation (Corbett et al., 1990).
Although several studies, using different antibodies, have
demonstrated a significant correlation between c-erbB-2 gene
amplification and immunohistochemical staining of c-erbB-2
protein (Venter et al., 1987; Slamon et al., 1989; Corbett et
al., 1990), evidence of overexpression has also been detected
in breast tumours in which the gene copy number was deter-
mined to be single (Slamon et al., 1989). In thyroid tumours,
no c-erbB-2 gene amplification has been found (Aasland et
al., 1988; Lemoine et al., 1990a), and it is therefore crucial to
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have optimal tissue quality and to exclude protein deter-
iorating procedures when looking for c-erbB-2 protein exp-
ression. In the present study, the staining intensity was
uniformly rather weak, although specific and reproducible.
The majority of immunopositive cases showed a specific
membrane staining as well as a weaker and more diffuse
cytoplasmic reaction. Two cases demonstrated almost exclus-
ively cytoplasmic staining, of stronger degree, and two cases
exhibited membrane staining only. The membrane staining
has been regarded as specific for c-erbB-2 protein expression
in breast carcinomas, and this staining pattern is associated
with gene amplification and of prognostic significance in
these tumours (Gullick et al., 1991; Lovekin et al., 1991).
In other human tumours, however, different staining pat-
terns have been observed. Diffuse cytoplasmic immunore-
activity was predominant in c-erbB-2 protein positive cases of
pancreatic cancer (Hall et al., 1990). In transitional cell car-
cinomas of the urinary bladder, cytoplasmic reactivity
predominated, even in tumours with high levels of gene
amplification (Coombs et al., 1991). The significance of
cytoplasmic staining has not yet been established. de Potter
et al. (1989) showed that the cytoplasmic reacting protein
was a protein of molecular weight 155 kD, different from the
known pls8erb52. In bladder tumours with high c-erbB-2
gene copy number and mRNA expression and cytoplasmic
staining, high levels of the 155 kD protein were detected
(Coombs et al., 1991). The close correlation of c-erbB-2 gene
amplification and cytoplasmic immunoreactivity in transi-
tional cell tumours argues that the cytoplasmic product does
represent a form of the c-erbB-2 protein, possibly reflecting
some alteration in processing or stability of the oncoprotein
or its mRNA. In the present study, cytoplasmic as well as
membrane staining was abolished when the primary antibody
was preincubated with the immunising c-erbB-2 peptide.
Our series includes five follicular carcinomas. None of
these stained positively in the immunohistochemical assay,
but the number of cases is too small to draw any conclusions
on c-erbB-2 expression in follicular thyroid carcinomas. The
only medullary carcinoma included was also negative. Ron-
calli and coworkers found that none out of 28 medullary
thyroid carcinomas displayed c-erbB-2 immunoreactivity
using the monoclonal antibody N3, but the authors comment
that fixation regimes might have adversely affected tumour
immunoreactivity (Roncalli et al., 1991).
c-erbB-2 mRNA was detected in all the samples analysed,
and the levels of c-erbB-2 mRNA in papillary carcinomas
and lymph node metastases were higher than the levels
observed in non-neoplastic tissue, comprising the groups nor-
mal thyroid tissue, colloid goitre and diffuse hyperplasia.
This observation is consistent with the previous findings by
Aasland et al. (1988). The higher levels ofc-erbB-2 mRNA in
the papillary carcinoma group were much lower than the
levels associated with gene amplification, in agreement with
what would be expected from the findings by Lemoine et al.
(1990a). It should, however, be kept in mind that our tumour
samples contain variable amounts of non-neoplastic tissue.
The contribution of c-erbB-2 mRNA and rRNA from non-
neoplastic tissue to the total RNA isolated must therefore
vary from specimen to specimen. Since rRNA most likely is
increased in proliferating tumour cells compared to non-
neoplastic cells, the increase in c-erbB-2 mRNA expression
that has been found in the papillary carcinoma samples, may
be underestimated. Consequently, the true increase in c-erbB-
2 mRNA per tumour cell may be higher than we report.
The significant increase in c-erbB-2 mRNA expression in
the papillary carcinoma group adds support to the protein
expression data from the immunohistochemical analysis. The
evidence of c-erbB-2 overexpression in the papillary car-
cinomas is, however, more clear from the immunohisto-
chemical results than from the RNA slot blot hybridisation
experiments. This is in agreement with Coombs and
coworkers who reported that 40% of tumours with no detec-
table c-erbB-2 amplification or overexpression which could be
detected by Northern or Western analysis, showed positive
c-erbB-2 immunostaining (Coombs et al., 1991). The con-
clusion from their work on bladder cancer is that immuno-
cytochemistry may be the most sensitive assay for detection
of c-erbB-2 expression. Slamon et al. (1989) also found that
immunohistochemical analysis of c-erbB-2 protein in frozen
tissue sections correlated best with all other analytic data for
both breast and ovarian cancer.
The function of the c-erbB-2 protein in cell growth and
development remains unknown. The protein has tyrosine
kinase activity, and is postulated to be a transmembrane
receptor (Yamamoto et al., 1986), for which a ligand has not
yet been fully established. The homology and close relation-
ship to the EGF-receptor suggest that the c-erbB-2 protein
may convey potent growth stimulatory signals. In human
tumours, overexpression and not mutation of the c-erbB-2
gene seems to contribute to tumour development (Slamon et
al., 1989; Lemoine et al., 1990b). In thyroid tumours also, no
activating point mutations of the transmembrane-encoding
region of the c-erbB-2 gene have been revealed (Lemoine et
al., 1990a).
Investigations on the role of growth factors and oncogenes
in the development of thyroid tumours have revealed that
activation of ras oncogenes (Lemoine et al., 1989; Suarez et
al., 1990) and autocrine production of IGF-I (Williams et al.,
1988) occur in the early stages of thyroid follicular cell
tumourigenesis, and TGF-P expression is associated with the
malignant stages (Jasani et al., 1990). The nuclear oncogenes
c-myc and c-fos have been found to be expressed at varying
levels in both non-tumour and tumour tissue, but neither
rearrangements nor amplifications of these oncogenes have
been observed in several studies (Aasland et al., 1988; Terrier
et al., 1988; Wyllie et al., 1989). The PTC and trk tyrosine
kinase oncogenes are activated in a number of papillary
carcinomas (Fusco et al., 1987; Bongarzone et al., 1989), the
PTC oncogene being a rearranged form of the ret oncogene
(Grieco et al., 1990).
The present work presents c-erbB-2 protein expression as a
feature of papillary thyroid carcinomas, extending the list of
human adenocarcinomas expressing this protein. The in-
creased expression of c-erbB-2 protein in papillary thyroid
carcinomas is not due to gene amplification, and no other
genetic aberration explaining this increased expression has
been identified. However, the large proportion of papillary
thyroid carcinomas expressing the c-erbB-2 protein indicates
a biologically significant mechanism involving this receptor
system in papillary carcinomas. Further investigations will be
needed to assign the biological significance and prognostic
implications of c-erbB-2 protein expression in these thyroid
tumours.
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